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Angina pectoris is a clinical indication that 
outcomes from coronary atherosclerotic 
coronary illness. An intense anginal assault 
(optional angina) is thought to happen in view 
of unevenness between myocardial oxygen 
flexibly and request attributable to the 
powerlessness of coronary blood stream to 
increment with respect to increments in 
myocardial oxygen prerequisites. This is 
commonly the aftereffect of extreme coronary 
vein atherosclerosis. Angina pectoris 
(variation, essential angina) may likewise 
happen because of vasospasm of enormous 
epicardial coronary vessels or one of their 
significant branches. Furthermore, angina in 
specific patients may result from a blend of 
coronary vasoconstriction, platelet collection, 
plaque break, and an expansion in myocardial 
oxygen request (crescendo or flimsy angina). 
According to the World Cardiovascular 
maladies Report (2019), an expected 17.9 
million individuals passed on from 
cardiovascular illnesses in 2016, speaking to 
31% of every worldwide demise. Of these 
passing, 85% are because of coronary failure 
and stroke. (1-4) 
Antianginal Drugs (3-7) 
Antianginal medications may soothe 
assaults of intense myocardial ischemia by 
expanding myocardial oxygen gracefully or by 
diminishing myocardial oxygen request or 
both. Three gatherings of pharmacological 
specialists have been demonstrated to be 
powerful in lessening the recurrence, 
seriousness, or both of essential or optional 
angina. These specialists incorporate the 
nitrates, β-adrenoceptor enemies. What’s more, 
calcium section blockers. To comprehend the 
gainful activities of these specialists, it is 
essential to be acquainted with the central 
point managing the harmony between 
myocardial oxygen gracefully and request. 
The Classes are: 
Vasodilators compounds (VC) 
The contractile movement of a wide range 
of muscle is controlled essentially by the 
reversible phosphorylation of myosin. Along 
with actin they take an interest in a course of 
biochemical occasions that are a piece of the 
procedures of muscle compression and 
unwinding. Nitrates shows vasodilating 
impact, which brings about decrease of fringe 
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obstruction during myocardial constrictions. 
The vasodilator meds under this class joins 
nitrates, calcium blocker, for example, 
Isosorbide dinitrate, Pentaerythritol 
tetranitrate, Isosorbide mononitrate and 
Nitroglycerin, and so on. 
Cardiac depressants compounds (CDC) 
Cardiac depressants compounds (CDC) like 
calcium blocker, and beta-blocker, for 
instance, verapamil, calcium particles assume a 
significant job in the guideline of numerous 
cell forms, for example, synaptic transmission 
and muscle constriction. Calcium channel 
blockers lessen or forestall the expansion of 
free cytosolic calcium particles by meddling 
with the vehicle of calcium particles through 
these pores. Ex. Atenolol, Propranolol, 
Metoprolol, Diltiazem and Verapamil, and so 
on. 
Miscellaneous compounds (MC) 
Miscellaneous compounds (MC) acts non‐
aerodynamically, forestalls corruption of layer 
unsaturated fats by lipid peroxidation 
decreases myocardial O2 request ‐ pFOX 
inhibitor and furthermore represses superoxide 
cytotoxicity ‐ shields myocin from unsafe 
impacts of ischemia. What's more, it squares 
late internal sodium flows in cardiomyocytes. 
In the ischemic myocardium, late internal 
sodium flows add to a rise in intracellular 
sodium, which prompts an expansion in 
intracellular calcium through the sodium-
calcium exchanger. Calcium over-burden in 
ischemic cells prompts hindered unwinding, 
cardio protective additionally restrains 
unsaturated fat oxidation. The various 
compounds under this characterization 
consolidates Ivabradine, Ranolazine and 
Trimetazidine, and so on. 
Angina pectoris is the consequence of 
myocardial ischemia brought about by 
unevenness between myocardial blood 
gracefully and oxygen request. It is a typical 
introducing side effect (commonly, chest 
torment) among patients with coronary artery 
disease (CAD). Roughly 9.8 million 
Americans are assessed to encounter angina 
yearly, with 500,000 new instances of angina 
happening each year. Individuals with a 
normal age of 62 years, who have moderate to 
extreme degrees of angina (reviewing by 
classes II, III, and IV) have a 5-year endurance 
pace of around 92%. (1) This overview 
moreover analyzes present day and front line 
distinctive consistent approaches to manage 
antianginal cure like ranolazine, methodology 
improvement with UV, HPLC, HPTLC, GC-
MS and LC-MS including the various 
methodologies. 
Ranolazine (ROZ) (8-10) 
Ranolazine (ROZ) is hinders persevering or 
late internal sodium current in heart muscle in 
an assortment of voltage-gated sodium 
channels. Repressing that present prompts 
decreases in intracellular calcium levels. This 
thus prompts diminished pressure in the heart 
divider, prompting decreased oxygen 
necessities for the muscle. Ranolazine likewise 
shows its consequences for the postponed 
rectifier current, it promptly invigorates 
myogenesis, it diminishes a genius oxidant 
irritation/oxidative condition, and actuates the 
calcium flagging pathway. The chemical name 
of ranolazine is N-(2, 6-dimethylphenyl) -2-{4-
[2-hydroxy -3-(2-methoxyphenoxy) propyl] 
piperazin-1-yl} acetamide. The atomic 
equation of ROZ is C12H33N3O4 and sub-
atomic load of ROZ is 427.537 g/mol. 
It has the following structural formula,
 
Figure 1. Structural formula of Ranolazine 
Ranolazine is white to off-white solid with 
dissolvability in natural solvents, for example, 
dichloromethane and methanol, sparingly 
soluble in tetrahydrofuran, ethanol, 
acetonitrile, and acetone, slightly solublein 
ethyl acetate, iso-propanol, toluene, and ethyl 
ether; and very slightly soluble in water. The 
partition coefficient (log p) for ROZ is 2.07 
and Pka is 2.2.
 
Ranolazine is a piperazine subordinate is 
another enemy of ischemic medication for the 
treatment of angina. Ranolazine is to restrain 
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late INa accordingly forestalling sodium over-
burden of the cell. As an outcome, ranolazine 
forestalls switch mode sodium–calcium trade 
and hence diastolic amassing of calcium 
perhaps bringing about improved diastolic tone 
and improved coronary blood stream. This 
audit article speaks to the different expository 
strategies which has been accounted for 
estimation of Ranolazine in manufactured 
blend. (2-4, 6,10) 
2. HPLC Method of Analysis of Antianginal 
Drugs 
High Performance Liquid 
Chromatography (HPLC) is a separation 
system, it disconnects mix containing in 
any event two sections under high 
pressure. In HPLC Stationary stage is full 
in one completion of fragment which is 
attached to a wellspring of pressurized 
liquid versatile stage. HPLC is a speediest 
creating logical method for the 
examination of the prescription. Its ease, 
high distinction and wide extent of 
affectability makes it ideal for the 
examination of various drugs in the two 
estimations structure and regular fluids. A 
couple HPLC procedures were 
represented the examination of antianginal 






Figure 2. HPLC Method of Analysis of Antianginal Drugs 
A summary of research take a shot at a 
few expository techniques (HPLC, UV, 
HPTLC, UPLC and MS) announced for 
the ranolazine alone and in blend is give 
in Table 1. 
Table 1. A summary of research work on the analytical methods for the estimation of 
ranolazine alone and in the combination 
Sr. 
No. 
Drug Method Instrument, Mobile Phase, RT, Flow Rate & 
Results of Validation 
1. Ranolazine UV-Method M.Phase :- Methanol 




Slope and intercept- 0.0061 and - 0.0118 
 Detection Limit (μg/mL)- 0.27 
Quantification limit (μg/mL)- 0.82 .(14) 
2. Ranolazine UV-Method   M.Phase :- 0.2% v/v ortho phosphoric acid  




Slope and intercept- 0.006 and 0.0048 
LOD - 0.807 μg/ml 
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LOQ - 2.4460 μg/ml (15) 
3. Ranolazine UV-Method  M.Phase :- Methanol and distilled water  





 LOD - 0.0072 
 LOQ - 0.021 (16) 
4. Ranolazine UV-Method   M.Phase :- Water 





Slope and intercept- 0.0482 and  0.0171 
 % RSD – 1.140 
 % Recovery- 99.99 (17) 
5. Ranolazine UV-Method M.Phase :- Synthetic mixture 





Slope and intercept- 0.0005 and  0.0104 
 % RSD :- less than 2 , 






UV-Method  M.Phase :- synthetic mixture 




0.9996 for ADH & 0.9996 for ROZ 
   LOD :- 0.712 μg/ml and 0.823 μg/ml 
   LOQ:- 0.235 μg/ml and 0.271 μg/ml (19) 
7. Ranolazine UV-Method 
& HPLC. 
 M.Phase :- 0.05M HCl 
 λmax :- 272 nm. 
Result :- 




  LOD :- 0.25 μg/ml ,  
  LOQ:- 1.00 μg/ml.  
   
  HPLC: 
  M.Phase :- Acetonitrile: 20 mM Ammonium acetate    
   buffer (55 : 45, v / v) 
   Flow Rate :- 1.0 ml/min at 270 nm 
   Result:- 
   R. Time :- 3.8 min.,  
   R
2-
0.9995 . 
   LOD :-  0.5 ng/ml 





LC-UV    M.Phase :- Acetonitrile: 0.02N NH2PO4 buffer (50:50,     
     v / v) 
   Flow Rate :- 1.0 ml/min at 282 nm 
   Result:- 
   R. Time :- 0.25 & 0.16 min.,  
   R
2-
0.9999. 
   LOD :- 0.39 and 0.58 ng/ml 
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   LOQ :- 1.19 and 1.76 ng/ml (21) 
9. Ranolazine LC-UV    M.Phase :- Acetonitrile – Sodium di-hydrogen  
  phosphate monohydrate buffer (40:60 v/v) 
  Flow Rate :- 1.0 ml/min at 225 nm 
  Result:- 




  LOD :- 1.03 ng/ml 
  LOQ :- 0.34 ng/ml (22) 
10. Ranolazine HPLC.   M.Phase :- Methanol-acetonitrile-phosphate buffer (pH   
    3.6; 6.3 mM) (4:3:3, v/v/v) 
  Flow Rate :- 1 ml/min at 254 nm 
  Result:- 




  LOD :- 0.04 μg/ml ,  
  LOQ:- 0.12 μg/ml. (23) 
11. Ranolazine HPLC.  M.Phase :- Methanol- phosphate buffer (pH-7) (65:35  v/v)  
  Flow Rate :- 1 ml/min at 220 nm 
  Result:- 




  LOD :- 0.0273 μg/ml 
  LOQ:- 0.0818 μg/ml (24) 
12. Ranolazine HPLC.  M.Phase :- Buffer- acetonitrile (90:10 v/v) and Acetonitrile- 
water (90:10 v/v) 
  Flow Rate :- 1 ml/min 
  Result:- 




  LOD :- 1000 μg/ml  




LC-UV.   M.Phase :- Methanol  
  Flow Rate :- 1.0 ml/min 
  λmax :- 254 nm. 
  Result:- 
  R. Time :- 4.7 & 6.4 min., 
  R
2-
0.997 & 0.999. 
  LOQ:- 0.8 & 1.1 μg/mL (26) 
14. Ranolazine RP-HPLC.   M.Phase :- Potassium dihydrogen phosphate monohydrate: 
methanol: acetonitrile (40:40:20) v/v  
  Flow Rate: - 1.2 ml/min at 225 nm. 
  Result:- 




  LOD:- 0.34 μg/mL 
  LOQ: - 1.03 μg/mL. (27) 
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15. Ranolazine HPLC in 
dog plasma 
sample. 
  M.Phase :- Acetonitrile-water(7 mmol·L-1 ammonium  
 acetate,3.5 mmol·L-1 acetic acid and 1‰ triethylamine)   
  (50:50) 
  Flow Rate: - 0.8 ml/min at 230 nm. 
  Result:- 




  % Recovery: - 88%-105%.(28) 
16. Ranolazine RP-HPLC.   M.Phase :- Sodium di-hydrogen phosphate buffer : 
Acetonitrile (60:40) v/v ) 
  Flow Rate :- 1.0 ml/min 
  Result:- 




  LOD:- 0.34 μg/mL 
  LOQ: - 1.03 μg/ml. (29) 
17. Ranolazine HPLC in 
Synthetic 
sample. 
  M.Phase :- hexane : 2-propanol (90 : 10)  
  Flow Rate :- 1 ml/min 
  Result:- 
  R
2-
  ˃0.988 
% RSD :- less than 2 , 
 % Recovery:- 92.18-96.17 (30) 
18. Ranolazine LLE-HPLC 
in human 
plasma 
  M.Phase :- Acetonitrile: phosphate buffer (pH 2, 20 mM) 
(40:60 v/v) 
  λmax :- 225nm 
  Results :-  
  R. Time :- 3.73 min., 
  R
2-
0.998.   
  LOQ: 80 μg/ml, (31) 
19. Ranolazine RP-UPLC 
Method 
  M.Phase :- Acetonitrile-Sodium dihydrogenphosphate  
 (pH7.3;0.01 M)-Triethylamine (10:90:0.1,v/v/v) 
   λmax :-  223 nm 




  R. Time :- 10.25 
  Detection Limit – 0.006 
  Quatification limit – 0.15 (32) 
20. Ranolazine  HPLC-FD, 
HPLC-UV,  
LC-MS/MS 
 in clinical 
pharmacoki
netics 
  HPLC-FD 
  M.Phase :- Methanol-Potassium phosphate monobasic  
    0.01 mol/L - Acetonitrile (45 : 40 : 15, v/v/v)   
  Flow rate; - 1 ml/min. 
  λmax :- 229 nm 
  
  HPLC 
  M.Phase:- N-heptane/2-propanol/alcohol 
   [ethanol]/diethylamine (60 : 15 : 25 : 0.2, v/v/v/v)  
  Flow rate ;-  1 ml/min. 
  λmax :- 229 nm 
 
  LC-MS/MS 
  M.Phase :- Water containing 0.1% formic acid &   
                    Acetonitrile containing 0.1% formic acid 
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  Flow rate ;-  1 ml/min. 
  λmax :- 223 nm (33) 
21. Ranolazine LC- MS/MS 
 in plasma 
 M.Phase :- 0.125 % v/v trifluoroacetic acid  in water 
adjusted to pH 3 with ammonia  
 Flow Rate: - 1. ml/min. 
 HPLC :- 




 Recovery:- 85%,  (34) 
22. Ranolazine LC-MS/MS  
in 
dog plasma 
 M.Phase:- Acetonitrile 0 05% acetic acid (60∶40, v/v) Flow 
Rate: - 2 ml/min. 




 Recovery:- 80-91%,  
 Absolute bioavability -72.6%  
 Peak concentration – 4.32 μg/mL (35) 
23. Ranolazine LC-MS/MS  
in human 
plasma 
 M.Phase :- Acetonitrile-0.1% formic acid (90∶10). 
 Flow Rate :- 1.0 ml/min. 
HPLC :- 




 Recovery:- 75% 
 LOQ:- 20 ng/ml (36) 
24. Ranolazine HPLC- MS 
in human 
plasma 
  M.Phase :- Methanol–10mM Ammonium acetate (60:40 v/v)  
  Flow Rate :- 1.0 ml/min. 
 HPLC :- 
  R. Time :- 1.93 min 
  LOD :- 1 ng/mL 
  LOQ:- 10 ng/mL (37) 
25. Ranolazine LC- EI-MS 
 in  Rat 
plasma 
  M.Phase :- Methanol–10 mM Ammonium acetate,  
                     (76:24 v/v).   
  Flow Rate :- 1.0 ml/min  
  HPLC :- 
  R. Time :- 4.2 min 
  Recovery :-  82.77–86.54%. 





   M.Phase :- Acetonitrile–Water–Formic acid– 10% N-
butylamine (70:30:0.5:0.08, v/v/v/v) 
   Flow Rate :- 5 μl/min 
   HPLC :- 
   R. Time :- 1.12 min 
   R
2- 
0.995. 
   LOQ:- 5 μg/ml (39) 
27. Ranolazine LC-MS/Ms 
in human 
plasma 
  M.Phase :- :- Methanol–Water containing formic acid (1.0%, 
v/v) (65:35, v/v) 
  Flow Rate :- 1.0 ml/min 
  Result:- 




  LOQ:- 5.0 ng/ml  (40) 
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 M.Phase :- 5 mM Ammonium acetate aq.- Methanol.  
Flow Rate :- 0.5 ml/min  
Result:- 




 Recovery:- 84.2 -108% 









 M.Phase :- :- Hexane:Ethanol (60/40, v/v)  
Flow Rate :- 10 μl /min 
Result:- 
 R. Time :- 5.66 & 13.54 min for ROZ 
                  3.36 & 4.10 min. for DROZ 
 R
2-
0.9873 & 0.9891 for ROZ 
      0.9953 & 0.9944 for DROZ 





 M.Phase :- Aqueous ammonium acetate (20 raM)and  
trifluoroacetic acid (TFA, 0.12%) : methanolic ammonium 
acetate (20 mM) and TFA (0.12%) (40: 60 v/v) 
 Flow Rate :- 1 ml/min 
 Result:- 




 Inter-assay variation:- 18.5% (43) 
31. Ranolazine LC-APCI-
MS in  
dog plasma. 
 M.Phase :- :- Acetonitrile-0.05%formic acid (60:40v/v) 
 Flow Rate :- 0.3 ml/min 
 Result:- 




 LOD:- 0.002 mg/mL 





 M.Phase  Acetonitrile - Aqueous ammonium acetate solution 
(40:60, v/v).  
 Flow Rate :- 0.35 ml/min 
Result:- 




 Recovery:- 85 – 100.4% 
 LOQ:- 1.0 ng/ml  (45) 
33. Ranolazine DRIFTS-
Method 
  M.Phase :- Potassium bromide 
  Detection :- 4000 and 650 cm
_1
 
  Std. Peak:- Carbonyl peak around 1689 cm. 
  Result:- 




  RSD:- 0.957-1.001 
  Recovery:- 95.58–97.12% (46) 
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34. Ranolazine HPTLC 
Method 
  M.Phase :- Chloroform : Methanol : Toluene (5 : 1 : 1 v/v/v)   
  λmax :-  273nm 
  Results :-  




  LOD:-  250 ng/spot 
  LOQ;-  440 ng/spot (47) 
35. Ranolazine HPTLC-MS   M.Phase :- Butanol–Acetic acid–water (6:2:2 v/v) 
  λmax :-  270 nm 
  Results :-  




  LOD:-  14.9 ng/band 
  LOQ;-  49.67 ng/band (48) 
36. Ranolazine Headspace 
GC 
 S.Phase :- DB-624 capillary column (30m×0.32mm×1.8μm)  
 Detector :- FID 
 % RSD :- 1.1-3.7% 
 Recovery:- 98.1%-105.5% (49) 
37. Ranolazine Headspace 
GC 
 S.Phase:-  HP-INNOWAX column 
 Solvent :- Water  
 Detector :- FID 
 % RSD of precision and accuracy:- less than 8% 
 Recovery:- 87.1%-105.6%.(50) 
 
3. Conclusion 
In spite of the way that couple of 
indicative procedures ( HPLC, UV, 
HPTLC, UPLC and MS) are represented 
there is a continued with necessity for 
developing continuously beneficial, 
sensitive, precise and accurate systems 
for the assessment of the ranolazine alone 
and in blend in the portion structures and 
in the natural fluids. The introduced data 
is valuable for the future examination for 
analyst associated with definition 
improvement and quality control of 
Ranolazine 
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